VIDEO: PSCA-targeted CAR T-cell therapy shows promise in prostate cancer subgroup
Click Here to Manage Email Alerts
In this video, Tanya Dorff, MD, discusses findings from a phase 1 study assessing prostate stem cell antigen-targeted CAR T-cell therapy in patients with castration-resistant prostate cancer.
The findings were presented at the 2022 ASCO Genitourinary Cancers Symposium.
Dorff, section chief of the genitourinary disease program at City of Hope, noted that while the data presented were early phase results, “what I would want clinicians to take away is that CAR T-cell therapy — in our case targeting prostate stem cell antigen (PSCA) — is already showing the potential for significant objective responses even as we’re very early along in [the] dose escalation or dose optimization phase.
“It’s not ready for primetime,” she added. “Not every patient is eligible, but we’re very excited that we’ve essentially validated PSCA as an effective target in advanced prostate cancer and also that it looks like CAR T-cell therapy will find a way forward with a little bit more work to optimize. But we’ll find a way into the therapeutic armamentarium, we believe.”
Collapse
Dorff T, et al. Poster 25. Presented at: ASCO Genitourinary Cancers Symposium; Feb. 17-19, 2022 (San Francisco).
Read more about
Click Here to Manage Email Alerts